167 related articles for article (PubMed ID: 21821127)
1. Expression, purification and structural characterization of functionally replete thrombospondin-1 type 1 repeats in a bacterial expression system.
Klenotic PA; Page RC; Misra S; Silverstein RL
Protein Expr Purif; 2011 Dec; 80(2):253-9. PubMed ID: 21821127
[TBL] [Abstract][Full Text] [Related]
2. CD36: a critical anti-angiogenic receptor.
Simantov R; Silverstein RL
Front Biosci; 2003 Sep; 8():s874-82. PubMed ID: 12957861
[TBL] [Abstract][Full Text] [Related]
3. CD36-TSP-HRGP interactions in the regulation of angiogenesis.
Silverstein RL; Febbraio M
Curr Pharm Des; 2007; 13(35):3559-67. PubMed ID: 18220792
[TBL] [Abstract][Full Text] [Related]
4. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.
Simantov R; Febbraio M; Crombie R; Asch AS; Nachman RL; Silverstein RL
J Clin Invest; 2001 Jan; 107(1):45-52. PubMed ID: 11134179
[TBL] [Abstract][Full Text] [Related]
5. Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth.
Hale JS; Li M; Sinyuk M; Jahnen-Dechent W; Lathia JD; Silverstein RL
PLoS One; 2012; 7(7):e40033. PubMed ID: 22808089
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36.
Klenotic PA; Page RC; Li W; Amick J; Misra S; Silverstein RL
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1655-62. PubMed ID: 23640500
[TBL] [Abstract][Full Text] [Related]
7. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.
Simantov R; Febbraio M; Silverstein RL
Matrix Biol; 2005 Feb; 24(1):27-34. PubMed ID: 15748999
[TBL] [Abstract][Full Text] [Related]
8. Expression and characterization of novel thrombospondin 1 type I repeat fusion proteins.
Qabar AN; Bullock J; Matej L; Polverini P
Biochem J; 2000 Feb; 346 Pt 1(Pt 1):147-53. PubMed ID: 10657251
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 (TSP-1), a new bone morphogenetic protein-2 and -4 (BMP-2/4) antagonist identified in pituitary cells.
Sallon C; Callebaut I; Boulay I; Fontaine J; Logeart-Avramoglou D; Henriquet C; Pugnière M; Cayla X; Monget P; Harichaux G; Labas V; Canepa S; Taragnat C
J Biol Chem; 2017 Sep; 292(37):15352-15368. PubMed ID: 28747434
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1.
Nunes SS; Outeiro-Bernstein MA; Juliano L; Vardiero F; Nader HB; Woods A; Legrand C; Morandi V
J Cell Physiol; 2008 Mar; 214(3):828-37. PubMed ID: 17879962
[TBL] [Abstract][Full Text] [Related]
11. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1.
Merle B; Malaval L; Lawler J; Delmas P; Clezardin P
J Cell Biochem; 1997 Oct; 67(1):75-83. PubMed ID: 9328841
[TBL] [Abstract][Full Text] [Related]
12. Affinity purification of recombinant proteins fused to calmodulin or to calmodulin-binding peptides.
Vaillancourt P; Zheng CF; Hoang DQ; Breister L
Methods Enzymol; 2000; 326():340-62. PubMed ID: 11036652
[No Abstract] [Full Text] [Related]
13. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication.
Tan K; Duquette M; Liu JH; Dong Y; Zhang R; Joachimiak A; Lawler J; Wang JH
J Cell Biol; 2002 Oct; 159(2):373-82. PubMed ID: 12391027
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondins as anti-angiogenic therapeutic agents.
Vailhé B; Feige JJ
Curr Pharm Des; 2003; 9(7):583-8. PubMed ID: 12570805
[TBL] [Abstract][Full Text] [Related]
16. Expression and initial characterization of a recombinant human thrombospondin heparin binding domain.
Yabkowitz R; Lowe JB; Dixit VM
J Biol Chem; 1989 Jun; 264(18):10888-96. PubMed ID: 2659597
[TBL] [Abstract][Full Text] [Related]
17. Expression in Escherichia coli and purification of human eosinophil-derived neurotoxin with ribonuclease activity.
Sun L; Li MS; Fisher LM; Spry CJ
Protein Expr Purif; 1995 Oct; 6(5):685-92. PubMed ID: 8535163
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats.
Iruela-Arispe ML; Lombardo M; Krutzsch HC; Lawler J; Roberts DD
Circulation; 1999 Sep; 100(13):1423-31. PubMed ID: 10500044
[TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.
Zhou J; Rothman VL; Sargiannidou I; Dimitrov S; Qiu C; Smith E; Sheffield J; Sharma M; Tuszynski GP
J Cell Biochem; 2004 May; 92(1):125-46. PubMed ID: 15095410
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin-1 type 1 repeats in a model of inflammatory bowel disease: transcript profile and therapeutic effects.
Lopez-Dee ZP; Chittur SV; Patel B; Stanton R; Wakeley M; Lippert B; Menaker A; Eiche B; Terry R; Gutierrez LS
PLoS One; 2012; 7(4):e34590. PubMed ID: 22509329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
